China's Fosun to Buy Huge Stake in India's Gland Pharma

Jul 27, 2016

The Economic Times

Fosun Pharmaceutical will sign an agreement to buy a controlling stake in India's Gland Pharma for $1.4 billion, according to the Economic Times. The Chinese firm is said to expand its research and manufacturing capacity in India.

According to Bloomberg, Shanghai-based Fosun has been the most active buyer in China’s healthcare industry, making 17 deals worth $1.6 billion since 2010, mainly investing in biosimilars and small molecule chemical drugs.

Fosun is said to acquire a 96 percent stake, however, another source said Gland will initially buy 86% of the company while Ravi Penmetsa and KKR & Co. may retain a 10% stake, the story said.

Read the full article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments